Atara Biotherapeutics (ATRA) Reports Q3 Loss of $4.20
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ATRA Hot Sheet
Join SI Premium – FREE
Atara Biotherapeutics (NASDAQ: ATRA) reported Q3 EPS of ($4.20), versus ($2.59) reported last year.
For earnings history and earnings-related data on Atara Biotherapeutics (ATRA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- aTyr Pharma (LIFE) Reports Q3 EPS of $0.53; Offers Guidance
- Neurocrine Biosciences (NBIX) Tops Q3 EPS by 138c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
